Nektar sues Lilly, claiming it hindered biotech’s autoimmune drug after buying Dermira

Nektar Therapeutics is taking Eli Lilly to court in California, saying the Indianapolis-based drugmaker mishandled data and “executed on a scheme to ensure that REZPEG would never succeed” after it bought another autoimmune drug candidate.

The lawsuit was filed in the US District Court for the Northern District of California…
Click here to view original post